Sign inCreate account

Report workspace tools

NCT06268327NOT_YET_RECRUITINGanonymous

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

Sponsor

Source record

Assiut University

Phase

Source record

Phase 2/3

Modality

AI-normalized

small molecule

Target

AI-normalized

Triple-negative breast cancer

Indication / condition

AI-normalized

Breast Cancer

Intervention

Source record

Cisplatin injection and gemcitabine, Capecitabine tablets

Source & freshness

Source record

NCT ID

NCT06268327

Original source

ClinicalTrials.gov

Source last updated

Feb 20, 2024

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06268327

Title

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

Sponsor

Assiut University

Status

NOT_YET_RECRUITING

Phase

Phase 2/3

Condition raw

Breast Cancer

Condition normalized

Breast Cancer

Modality raw

Breast Cancer

Modality normalized

small molecule

Target raw

Triple-negative breast cancer

Target normalized

Triple-negative breast cancer

Interventions

Cisplatin injection and gemcitabine, Capecitabine tablets

Public preview

Source record

This clinical trial aims to evaluate the efficacy and toxicity of adjuvant cisplatin and gemcitabine compared to capecitabine in patients with triple-negative breast cancer who have not achieved a pathological complete response after neoadjuvant chemotherapy. The study is sponsored by Assiut University and is set to begin recruiting in April 2024.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06268327

Status

NOT_YET_RECRUITING

Phase

Phase 2/3

Sponsor

Assiut University

Executive brief

Investment-Ready Snapshot

This clinical trial aims to evaluate the efficacy and toxicity of adjuvant cisplatin and gemcitabine compared to capecitabine in patients with triple-negative breast cancer who have not achieved a pathological complete response after neoadjuvant chemotherapy. The study is sponsored by Assiut University and is set to begin recruiting in April 2024.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 20, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06268327

Indication

Breast Cancer

Modality

small molecule

Target

Triple-negative breast cancer

Intervention

Cisplatin injection and gemcitabine, Capecitabine tablets

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.